Tetra Bio-Pharma Inc.
TBPMQ
$0.00
$0.000.00%
OTC PK
| 08/31/2022 | 05/31/2022 | 02/28/2022 | 11/30/2021 | 08/31/2021 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -56.78% | -35.54% | -11.20% | 29.46% | 51.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -61.68% | -49.89% | -30.70% | 17.91% | 71.17% |
| Operating Income | 61.68% | 49.89% | 30.70% | -17.91% | -71.17% |
| Income Before Tax | -33.97% | -46.34% | -87.90% | -156.48% | -76.92% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -33.97% | -46.34% | -87.90% | -156.48% | -76.92% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -135.28% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.55% | -23.75% | -53.96% | -109.96% | -82.47% |
| EBIT | 61.68% | 49.89% | 30.70% | -17.91% | -71.17% |
| EBITDA | 61.93% | 50.17% | 31.01% | -17.68% | -71.22% |
| EPS Basic | 7.74% | 8.02% | -8.39% | -49.53% | -38.99% |
| Normalized Basic EPS | 63.88% | 56.22% | 40.14% | 0.00% | -33.43% |
| EPS Diluted | 7.74% | 8.02% | -8.39% | -49.53% | -38.99% |
| Normalized Diluted EPS | 63.88% | 56.22% | 40.14% | 0.00% | -33.43% |
| Average Basic Shares Outstanding | 23.60% | 33.96% | 43.60% | 41.10% | 38.97% |
| Average Diluted Shares Outstanding | 23.60% | 33.96% | 43.60% | 41.10% | 38.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |